After a series of staff consolidation moves in recent weeks, Novartis is again trimming its ranks, albeit in what appears to ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

As the wave of in vivo CAR-T hype crests, Create Medicines is catching the swell with a $122 million series B meant to back ...

When Daniel Haders, Ph.D., was working in venture capital, he was on the hunt for an AI-driven drug discovery company that ...

Regenxbio’s gene therapy for Duchenne muscular dystrophy has smashed the primary endpoint of its pivotal trial, securing a ...

Aardvark Therapeutics is planning to unblind data from its phase 3 Prader-Willi syndrome (PWS) program after the FDA put a ...

If any proof was needed that big money is still available for AI drug development, look no further than the ten-figure series B hauled in by Isomorphic Labs. The London-based AI drug discovery firm ...

NeuroVision, which is working toward regulatory approval for its early Alzheimer’s detection technology, has acquired fellow diagnostics maker Durin Life Sciences for an undisclosed price. With the ...

A phase 2 trial of Biogen and Ionis Pharmaceuticals’ tau-targeting candidate missed its primary endpoint. But while the ...

Alumis is exploring strategic alternatives for its would-be rival to Amgen’s Tepezza, choosing to punt the program rather ...

Tech provider Signant Health announced the acquisition of Ametris to unite its electronic clinical outcome assessments (eCOA) ...

Valneva is planning to shrink its headcount by up to 15% as the French vaccine developer continues to seek ways to cut costs.